ERA June 1 - 2025 Supporting materials POSTER: Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity PRESENTATION: Sibeprenlimab for Patients With IgA Nephropathy Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study POSTER: Treatment Patterns of Primary Immunoglobulin A Nephropathy (IgAN) in China: Evidence from a Real-World Study using Regional Electronic Health Record Data POSTER: Clinical characteristics, and disease progression in primary IgA nephropathy patients in the Netherlands POSTER: Disease Progression and Its Association with Proteinuria Among Patients with Primary Immunoglobulin A Nephropathy (IgAN): Results from a Real-World Study in China
